Dr. Roy D. Baynes, M.D., Ph.D., serves as Senior Vice President of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories. Prior to Merck, Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics and Senior Vice President of Oncology Therapeutics at Gilead Sciences Inc. Prior, Dr. Baynes was Vice President of Global Clinical Development and Head of Hematology & Oncology at Amgen Inc., after serving as Vice President of Oncology for Supportive Care. Before joining Amgen in 2002, he was the Head Professor of Cancer Research and director of the Bone Marrow Transplant Program and the Hematological Malignancies Multidisciplinary Clinic at the Barbara Ann Karmanos Cancer Institute, a comprehensive cancer center at Wayne State University in Detroit, Michigan. There, he also held the positions of Professor of Medicine and Professor of Oncology. Dr. Baynes has been an Independent Director of Retrophin, Inc. since 2016.
Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. He is a member or fellow of several medical societies and has published more than 200 peer-reviewed articles and abstracts. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital. He has had a long and distinguished career in the hematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has been recurrently named among America’s top physicians.